Texas Sues Eli Lilly Over Alleged Unlawful Drug Promotion Practices

Texas Attorney General Ken Paxton has initiated legal proceedings against pharmaceutical company Eli Lilly, alleging that the firm engaged in unlawful practices to promote its medications, notably the GLP-1 receptor agonists Mounjaro and Zepbound, used for weight loss and diabetes management. The lawsuit contends that Eli Lilly provided illegal incentives to healthcare providers, including complimentary nursing services and reimbursement support, to encourage the prescription of its drugs. These actions, according to the complaint, led to substantial Medicaid claims in Texas that were influenced by these alleged inducements, potentially violating the Texas Health Care Program Fraud Prevention Act. Paxton stated, “Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme.” ([texasattorneygeneral.gov](https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturer-eli-lilly-bribing-providers-prescribe?utm_source=openai))

This legal action builds upon previous efforts by the Attorney General to hold pharmaceutical companies accountable for alleged fraudulent practices. In October 2024, Paxton filed a lawsuit against major insulin manufacturers and pharmacy benefit managers, including Eli Lilly, accusing them of conspiring to artificially inflate insulin prices by up to 1,000%. ([texasattorneygeneral.gov](https://texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers?utm_source=openai))

Eli Lilly has refuted the current allegations, asserting that similar claims brought by the same corporate relator have been dismissed by multiple courts and the federal government for lacking merit. A company spokesperson emphasized their intention to “vigorously defend against these allegations.” ([news.bloomberglaw.com](https://news.bloomberglaw.com/white-collar-and-criminal-law/texas-accuses-eli-lilly-of-inducing-providers-to-prescribe-drugs?utm_source=openai))

The outcome of this lawsuit could have significant implications for pharmaceutical marketing practices and the regulatory landscape governing interactions between drug manufacturers and healthcare providers.